FSHR
Follicle-stimulating hormone receptor
Also known as: FSHR_HUMAN, FSHRO, LGR1, ODG1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P23945
- Gene
- FSHR
- Ensembl
- ENSG00000170820
- Chromosome
- 2
- Canonical length
- 695 aa
- Protein class
- Disease related genes, FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters
- Secretome location
- Intracellular and membrane
- Quaternary structure
- Homotrimer
OverviewNCBI Gene
The protein encoded by this gene belongs to family 1 of G-protein coupled receptors. It is the receptor for follicle stimulating hormone and functions in gonad development. Mutations in this gene cause ovarian dysgenesis type 1, and also ovarian hyperstimulation syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2010]
Canonical amino-acid sequenceUniProt
695 residues, UniProt reviewed canonical sequence.
>P23945|FSHR
1 MALLLVSLLA FLSLGSGCHH RICHCSNRVF LCQESKVTEI PSDLPRNAIE LRFVLTKLRV
61 IQKGAFSGFG DLEKIEISQN DVLEVIEADV FSNLPKLHEI RIEKANNLLY INPEAFQNLP
121 NLQYLLISNT GIKHLPDVHK IHSLQKVLLD IQDNINIHTI ERNSFVGLSF ESVILWLNKN
181 GIQEIHNCAF NGTQLDELNL SDNNNLEELP NDVFHGASGP VILDISRTRI HSLPSYGLEN
241 LKKLRARSTY NLKKLPTLEK LVALMEASLT YPSHCCAFAN WRRQISELHP ICNKSILRQE
301 VDYMTQARGQ RSSLAEDNES SYSRGFDMTY TEFDYDLCNE VVDVTCSPKP DAFNPCEDIM
361 GYNILRVLIW FISILAITGN IIVLVILTTS QYKLTVPRFL MCNLAFADLC IGIYLLLIAS
421 VDIHTKSQYH NYAIDWQTGA GCDAAGFFTV FASELSVYTL TAITLERWHT ITHAMQLDCK
481 VQLRHAASVM VMGWIFAFAA ALFPIFGISS YMKVSICLPM DIDSPLSQLY VMSLLVLNVL
541 AFVVICGCYI HIYLTVRNPN IVSSSSDTRI AKRMAMLIFT DFLCMAPISF FAISASLKVP
601 LITVSKAKIL LVLFHPINSC ANPFLYAIFT KNFRRDFFIL LSKCGCYEMQ AQIYRTETSS
661 TVHNTHPRNG HCSSAPRVTS GSTYILVPLS HLAQNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against FSHR can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 7
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 2.6 nTPM
Expression across tissuesHPA
Tissue
- ovary: 2.6 nTPM
- testis: 2.1 nTPM
- heart muscle: 0.3 nTPM
- gallbladder: 0.2 nTPM
- blood vessel: 0.1 nTPM
- fallopian tube: 0.1 nTPM
Single-cell type
- sertoli cells: 470 nCPM
- granulosa cells: 132 nCPM
- bergmann glia: 78 nCPM
- medullary thymic epithelial cells: 43 nCPM
- adipocytes: 26 nCPM
- ovarian stromal cells: 19 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- hypothalamus: 2.6 nTPM
- midbrain: 2.1 nTPM
- medulla oblongata: 1.8 nTPM
- thalamus: 1.5 nTPM
- white matter: 1.3 nTPM
- spinal cord: 1.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FSHR.
Disease | AllUniProt
Conditions FSHR is implicated in, by any mechanism.
- Ovarian dysgenesis 1 (ODG1) MIM:233300
- Ovarian hyperstimulation syndrome (OHSS) MIM:608115
Disease | GeneticClinVar
35 pathogenic / likely-pathogenic of 230 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Ovarian dysgenesis 1
- Ovarian hyperstimulation syndrome
- Genetic non-acquired premature ovarian failure
- Dizygotic twins
- Amenorrhea
ReferencesPubMed · IEDB
Publications for FSHR from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Evidence for the presence of follicle-stimulating hormone receptor antibody in human serum.
1982 · Fertil Steril · RCR 0.7 · 22 citations - Follicle-stimulating hormone receptor autoantibody associated primary ovarian insufficiency successfully treated with corticosteroids: a case report.
2020 · F S Rep · RCR 0.6 · 9 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.22
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.8
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- adenylate cyclase-activating G protein-coupled receptor signaling pathway
- adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
- basement membrane organization
- cellular response to follicle-stimulating hormone stimulus
- female gamete generation
- female gonad development
- follicle-stimulating hormone signaling pathway
- G protein-coupled receptor signaling pathway
- gonad development
- hormone-mediated signaling pathway
- intracellular water homeostasis
- locomotory behavior
- male gonad development
- negative regulation of bone resorption
- neuron projection development
- phospholipase C-activating G protein-coupled receptor signaling pathway
- positive regulation of ERK1 and ERK2 cascade
- positive regulation of intracellular estrogen receptor signaling pathway
- positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
- primary ovarian follicle growth
- regulation of chromosome organization
- regulation of hormone metabolic process
- regulation of osteoclast differentiation
- regulation of platelet-derived growth factor receptor signaling pathway
- regulation of protein kinase A signaling
- regulation of systemic arterial blood pressure
- Sertoli cell development
- Sertoli cell proliferation
- sperm DNA condensation
- spermatogenesis
- transcytosis
- uterus development
- regulation of acetylcholine metabolic process
Molecular functions
- G protein-coupled peptide receptor activity
- peptide hormone binding
- follicle-stimulating hormone receptor activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- G protein-coupled receptor, rhodopsin-like
- Leucine-rich repeat N-terminal domain
- Glycoprotein hormone receptor family
- GPCR, rhodopsin-like, 7TM
- BspA-type LRR region
- Leucine-rich repeat domain superfamily
- 7 transmembrane receptor (rhodopsin family)
- Leucine rich repeat N-terminal domain
- BspA type Leucine rich repeat region (6 copies)
- Follicle stimulating hormone receptor
- Gonadotropin hormone receptor, transmembrane domain
- Gonadotropin hormone receptor transmembrane region
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of FSHR in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FSHR as an antibody target. Whether an autoantibody or antibody against FSHR could matter depends on whether native FSHR is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FSHR is annotated at the cell surface, where native FSHR is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label FSHR as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...